Industry Updates

Vertex Grabs $105M in Amended Telaprevir Deal with Mitsubishi | Xconomy30 Jul

More creative biotech funding, this time from Boston-based Vertex to develop and market their Hepatitis C protease inhibitor Telaprevir. Mitsubishi Tanabe Pharma is putting $105M of its money where its mouth is for the rights to market this potential blockbuster in Asia.

 http://www.xconomy.com/boston/2009/07/30/vertex-grabs-105m-in-amended-telaprevir-deal-with-mitsubishi/

Leave a Reply

Company News

  • - 2013/03/04

    One of our team members is now working with Hospira on infuser product support. Contact us to find out more!

  • - 2010/10/24

    We're currently working with online elections provider Everyone Counts, Inc. Contact us to find out more!

Contact Us